Completed PHASE1 INTERVENTIONAL 1-arm NCT01723553

Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

Sponsor: Mayo Clinic

Conditions Atypical Alzheimers Disease Logopenic Variant of Primary Progressive Aphasia (LPA) Posterior Cortical Atrophy (PCA)

Interventions C-11 PiB

Updated 6 times since 2017 Last updated: Dec 18, 2015 Started: Nov 30, 2012 Primary completion: Mar 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01723553, this PHASE1 trial focuses on Atypical Alzheimers Disease and Logopenic Variant of Primary Progressive Aphasia (LPA) and remains completed. Sponsored by Mayo Clinic, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States